We then investigated whether CsA treatment could exert a restorative action in a transgenic mouse model of Parkinson’s disease whereby the expression of wild-type human α-synuclein is driven by the neuronal promoter Thy-1 [48]. This evidence concerns the gene SNCA and Parkinson disease.